0000947871-22-000628.txt : 20220520 0000947871-22-000628.hdr.sgml : 20220520 20220520163215 ACCESSION NUMBER: 0000947871-22-000628 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220518 FILED AS OF DATE: 20220520 DATE AS OF CHANGE: 20220520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thompson Peter A. CENTRAL INDEX KEY: 0001357522 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40236 FILM NUMBER: 22948113 MAIL ADDRESS: STREET 1: C/O ANTHERA PHARMACEUTICALS, INC. STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B CITY: HAYWARD STATE: CA ZIP: 94545 FORMER NAME: FORMER CONFORMED NAME: Thompson Peter A DATE OF NAME CHANGE: 20060327 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc. CENTRAL INDEX KEY: 0001710072 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821725586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3415 COLORADO AVE. CITY: BOULDER STATE: CO ZIP: 80303 BUSINESS PHONE: 303-735-8373 MAIL ADDRESS: STREET 1: 3415 COLORADO AVE. CITY: BOULDER STATE: CO ZIP: 80303 4 1 ownership.xml X0306 4 2022-05-18 0 0001710072 Edgewise Therapeutics, Inc. EWTX 0001357522 Thompson Peter A. C/O EDGEWISE THERAPEUTICS, INC. 3145 COLORADO AVE. BOULDER CO 80303 1 0 1 0 Common Stock 2022-05-18 4 P 0 138000 7.21 A 13497456 I See Footnotes Common Stock 319599 I See Footnotes These shares of the Issuer's common stock ("Shares") were purchased in multiple transactions at prices ranging from $7.04 to $7.24. The price reported reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote. The Shares are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI. The Shares are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund. Each of the Reporting Person, GP VI, OrbiMed Advisors, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors has designated the Reporting Person, a member of of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Person, GP VI, OrbiMed Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. /s/ Peter A. Thompson 2022-05-20